These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36376516)

  • 1. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
    Knight A; Piskacek M; Jurajda M; Prochazkova J; Racil Z; Zackova D; Mayer J
    Cancer Immunol Immunother; 2023 May; 72(5):1209-1224. PubMed ID: 36376516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing.
    Hudecek R; Kohlova B; Siskova I; Piskacek M; Knight A
    Front Immunol; 2021; 12():752646. PubMed ID: 34691070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
    Knight A; Mackinnon S; Lowdell MW
    Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells.
    Siegers GM; Dhamko H; Wang XH; Mathieson AM; Kosaka Y; Felizardo TC; Medin JA; Tohda S; Schueler J; Fisch P; Keating A
    Cytotherapy; 2011 Jul; 13(6):753-64. PubMed ID: 21314241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
    D'Asaro M; La Mendola C; Di Liberto D; Orlando V; Todaro M; Spina M; Guggino G; Meraviglia S; Caccamo N; Messina A; Salerno A; Di Raimondo F; Vigneri P; Stassi G; Fourniè JJ; Dieli F
    J Immunol; 2010 Mar; 184(6):3260-8. PubMed ID: 20154204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of γδ T cell subsets induced from peripheral blood mononuclear cells of HIV/AIDS patients in vitro].
    Chen WW; Wu XL; Nie WM; Xie YX; Wang L; Zhao M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Mar; 28(3):285-7. PubMed ID: 22394638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
    Maeurer MJ; Martin D; Walter W; Liu K; Zitvogel L; Halusczcak K; Rabinowich H; Duquesnoy R; Storkus W; Lotze MT
    J Exp Med; 1996 Apr; 183(4):1681-96. PubMed ID: 8666926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the gammadelta T cell response to acute leukemia.
    Meeh PF; King M; O'Brien RL; Muga S; Buckhalts P; Neuberg R; Lamb LS
    Cancer Immunol Immunother; 2006 Sep; 55(9):1072-80. PubMed ID: 16328383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
    Chang YC; Chiang YH; Hsu K; Chuang CK; Kao CW; Chang YF; Chang MC; Lim KH; Cheng HI; Hsu YN; Chen CG
    Blood Cancer J; 2021 Nov; 11(11):182. PubMed ID: 34785653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccination influences subtypes of γδ-T cells during pregnancy.
    Wang L; Li J; Jiang S; Li Y; Guo R; Chen Y; Chen Y; Yu H; Qiao Q; Zhan M; Yin Z; Xiang Z; Xu C; Xu Y
    Front Immunol; 2022; 13():900556. PubMed ID: 36311780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of interferon-β in multiple sclerosis increases Vδ1
    Maimaitijiang G; Watanabe M; Shinoda K; Isobe N; Nakamura Y; Masaki K; Matsushita T; Yoshikai Y; Kira JI
    J Neuroinflammation; 2019 Sep; 16(1):179. PubMed ID: 31519178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
    Kreutzman A; Rohon P; Faber E; Indrak K; Juvonen V; Kairisto V; Voglová J; Sinisalo M; Flochová E; Vakkila J; Arstila P; Porkka K; Mustjoki S
    PLoS One; 2011; 6(8):e23022. PubMed ID: 21857985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and functional heterogeneity of peripheral γδ T cells in pulmonary TB and HIV patients in Addis Ababa, Ethiopia.
    Negash M; Tsegaye A; Wassie L; Howe R
    BMC Infect Dis; 2018 Sep; 18(1):464. PubMed ID: 30219039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.